Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 1.00 |
| ▸ | PPARA | Q07869 | 9/20 | 1.00 |
| ▸ | PPARD | Q03181 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1650684 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL6604515 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL27568074 | 1.00 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL6602393 | 0.97 | PPARG (0.94) | PPARGPPARAPPARD | |
| SCHEMBL27568030 | 0.97 | PPARG (0.94) | PPARGPPARAPPARD | |
| SCHEMBL6602397 | 0.97 | PPARG (0.94) | PPARGPPARAPPARD | |
| SCHEMBL6602380 | 0.97 | PPARG (0.94) | PPARGPPARAPPARD | |
| SCHEMBL6603468 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL6603462 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD | |
| SCHEMBL6603450 | 0.96 | PPARG (0.92) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| CN-118922890-A | Measurement, diagnosis, treatment and management of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-11-08 | — | — | CN | claimed |
| CN-114773930-B | Manufacturing method of hand-painted wall painting | 南阳理工学院 | 2024-02-27 | — | — | CN | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-20110092524-A1 | Agent for Enhancing Corneal Epithelial Barrier Function | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-2253325-A1 | AGENT FOR ENHANCING CORNEAL EPITHELIAL BARRIER FUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20040091407-A1 | Novel process for preparing crystalline particles | SMITHKLINE BEECHAM CORPORATION | 2004-05-13 | — | — | US | claimed |
| EP-1102757-B1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LTD (GB) | 2004-04-14 | — | — | EP | claimed |
| EP-1294362-A1 | NOVEL PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | claimed |
| US-6498174-B1 | AGONISTS TO PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; MODULATING BLOOD GLUCOSE AND LIPID LEVELS; REDUCING DYSLIPIDEMIA AND HYPERINSULINEMIA ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROME | SMITHKLINE BEECHAM CORPORATION | 2002-12-24 | — | — | US | claimed |
| WO-2002000200-A1 | NOVEL PROCESS FOR PREPARING CRYSTALLINE PARTICLES | GLAXO GROUP LIMITED (GB) | 2002-01-03 | — | — | WO | claimed |
| CN-1321152-A | Substituted oxazole and thiazole derivatives as hPPAR gamma and hPPAR alpha activators | GLAXO GROUP LTD (GB) | 2001-11-07 | — | — | CN | claimed |
| WO-2001057001-A1 | OXAZOLETHOXYPHENYLPROPANOIC ACID DERIVATIVE AS NIDDM- MEDICAMENT | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3823631-B1 | METHODS OF TREATING HFPEF EMPLOYING DAPAGLIFLOZIN AND COMPOSITIONS COMPRISING THE SAME | ASTRAZENECA AB (SE) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2001057001-A1 | OXAZOLETHOXYPHENYLPROPANOIC ACID DERIVATIVE AS NIDDM- MEDICAMENT | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | disclosed |
| EP-1102757-A1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008002-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | PPARG 3339/4885PPARA 2387/4885PPARD 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.